Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is markedly higher in younger and never-smoker p...

Full description

Bibliographic Details
Main Authors: Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2022-10-01
Series:Drugs in Context
Subjects:
alk
lung adenocarcinoma
nsclc
ntrk
ros1
tki
Online Access:https://www.drugsincontext.com/non-small-cell-lung-cancer-how-to-manage-alk-ros1-and-ntrk-rearranged-disease

Internet

https://www.drugsincontext.com/non-small-cell-lung-cancer-how-to-manage-alk-ros1-and-ntrk-rearranged-disease

Similar Items